BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
Strengths and limitations -this paragraph should be more clear what is a strength and what is a limitation. Also, you say omics approaches are inherently unbiased but you should be more specific -while they are 'agnostic', they suffer similar types of bias to traditional epidemiology (eg selection bias) and may even introduce technical bias p7 line 49 -please give more details on the how participants will be recruited-will all women who are eligible be invited at their first contact with the clinic? Who will invite them? p9 line 50 -will other data that may affect microbial composition be collected (eg antibiotic use?) p10 line 17. It is good there is a procedure in place to evaluate acute infections. Will you also include retrospective questions in case women do not report the fever at the time? What about serology for subclinical infections? p11 data analysis: Again it would be useful to clearly report the numbers for whom these assays are planned p13 descriptive data: The first paragraph is rather unnecessary: You could just say appropriate descriptive statistics will be applied p13 descriptive data: The second paragraph is rather light and it is understandable if the data analysis plan is still to be developed, particularly considering the complexity of what is proposed. You may consider separating the laboratory/data pre-processing and statistical analysis sections (ie you mention mixed models on page 11 and they could be moved here). Line 37 needs to be expanded -do you mean the number of tests (and there for p value correction) may change if a more targeted research question is pursued? And/or you may consider only nominally significant associations? Do you have an idea of how you will address the high dimensionality of omic x omic x time? will you also apply multivariate or variable selection models? while your sample size analysis suggests a modular analysis will be feasible, different approaches will likely be required for genome-wide analyses.
Ethical considerations. A thorough procedure involving community participants appears to be followed. It appears the main issues are the intensive blood sampling. -Do you have any references or data regarding potential adverse effects among pregnant women? The other issue are the vulnerable women involved -what consideration was paid to the level of compensation? Too high an incentive may had unfairly pressured some women to take part, despite the potential (small) risks involved.
Discussion -you may want to elaborate on the plans for the samples and data collected for women not taking part in the initial case-control analysis. This will be a valuable birth cohort and other analyses with continuous outcomes (eg birthweight) may also address some of the power issues. Are there plans/funding to stay in touch with the families after three months post-partum?
REVIEWER
Kenichi Sakurai Chiba University, Center for Preventive Medical Sciences REVIEW RETURNED 30-Jul-2018
GENERAL COMMENTS To the authors
This manuscript explains an interesting cohort study protocol. In this manuscript, this study contains interesting field, such as transcriptome or microbiome. I look forward to their future findings. For the benefit of the readers, however, several points need clarifying and certain statements require further understanding. These are given below.
1. When will the authors start this cohort study? How long will they recruit their participants?
2. The sample size needs justifying. It would be helpful to include a sample size calculation.
3. The authors should describe the statistical methods to evaluate mRNA expression, microbiota composition and others. It will be helpful for the readers to understand the protocol (sample size setting etc.). Will the authors evaluate their data using adjustment for multiple testing, such as Bonferroni's method?
4. The authors should describe manufactures' name of the reagents they will use.
5. It seems to be difficult for me to understand figure 2. I would appreciate it if the authors can change it for easy understanding.
6. There are both descriptions, 16S rRNA gene sequencing and 16S rDNA sequencing. It is necessary to unify the expressions.
7. The authors should spell out the abbreviations which appeared for the first time.
VERSION 1 -AUTHOR RESPONSE
Point-by-point response to the reviews comments/questions
Reviewer: 1
Reviewer Name: Oliver Robinson, School of Public Health, Imperial College London, UK I congratulate the authors on this exciting and important study. Generally, the manuscript is thorough and clearly written. I have just a few suggestions for improvement:
Response: we would like to thank Dr. Robinson for his valuable input and encouraging words.
Abstract: It would helpful to state the numbers for whom the omics analyses will be performed. I understand the protocol covers a complete set of analyses for 30 cases and 30 controls, but samples will be available for the full 400 (who stay in study). Please could you elaborate -also it appears initially it will therefore be a nested case-control design Response:
Since 'preterm' is a phenotype that cannot be predicted at this point, the total number needed for this prospective project (n=400) based on the historic relative frequency of preterm birth at the recruitment site, which is approximately 8%. Hence, we expect approximately 30 preterm deliveries from this cohort. However, all cases of preterm birth will be included in the case-control analysis, also to increase statistical power if more than 30 are available. From preliminary data, we know that the preterm rate in the study cohort is roughly following this estimate.
As suggested, the fact that the analysis will follow a nested case-control approach was added to the abstract. (see revised manuscript, line 61-62, 64, 308).
This design permits using samples to establish baseline "molecular trajectories" of healthy pregnancies or investigate perturbations of such trajectories during unwell fever visits which are common in the tropical regions.
Strengths and limitations -this paragraph should be more clear what is a strength and what is a
limitation. Also, you say omics approaches are inherently unbiased but you should be more specificwhile they are 'agnostic', they suffer similar types of bias to traditional epidemiology (eg selection bias) and may even introduce technical bias
Response:
While this extensive prospective research project has its strengths, the authors acknowledge that it also has its limitations. Since BMJ Open allows only 5 bullet points summarizing strength and limitations following the abstract, the authors tried to prioritize these. However, according to the reviewers' suggestion, traditional epidemiologic and technical biases in transcriptome analysis were added. (see revised manuscript, line 87-89, 98-100, 654, 673-675) p7 line 49 -please give more details on the how participants will be recruited-will all women who are eligible be invited at their first contact with the clinic? Who will invite them?
SMRU runs walk-in antenatal care clinics free of charge to the marginalized populations surrounding the clinics which are located in rural areas. All pregnant women who meet the inclusion criteria will be informed about the study in their preferred language by trained counsellors. Since the recruitment window lies between an estimated gestational age of 8 and <14 weeks, information about the study is not necessarily given at the first contact with the clinic (e.g. if the EGA is less than 8 at the first contact). Published results of this project will include the number of eligible women who registered to the SMRU ANC program during the recruitment period, how many of them were eligible for the study and how many where given information about the study. p9 line 50 -will other data that may affect microbial composition be collected (eg antibiotic use?)
As reviewer #1 pointed out, antibiotics influence the microbial composition. Use of concomitant medication will be captured together with clinical information in the event of a febrile or unwell episode such as asymptomatic malaria. Antibiotic use will also be recorded whenever prescribed by clinic health care staff but also if prescribed by other health care facilities. All drugs prescribed (antibiotics, antimalarials, antihelminthics, antihypertensives, antiglycemic etc will be recorded) (see revised manuscript, line 296-298) p10 line 17. It is good there is a procedure in place to evaluate acute infections. Will you also include retrospective questions in case women do not report the fever at the time? What about serology for subclinical infections?
From experience we know that pregnant women who follow SMRU antenatal care clinics usually report to theses clinics should there be any complications. On one hand this owed to the fact that all women are encouraged to report to the study clinic in the event of an illness, on the other hand due to the lack of availability and/or accessibility to other health care facilities in the vicinity. However, should a study participant receive treatment (e.g. antibiotics) from another source, we aim to capture these details during the next routine follow up visit.
No standard serological assessments for subclinical infections are planned as yet. However, there is a plan to assess subclinical/sub-microscopic malaria infections by qPCR.
From a non-clinical viewpoint attempting to identify subclinical infections may be a fruitful path for further investigation with the samples. E.g. spikes in interferon responses could be hypothesized to be associated with undiagnosed viral infections -it would then be possible to examine frequency of adverse outcomes (maternal, fetal, in infancy and later in life).
p11 data analysis: Again it would be useful to clearly report the numbers for whom these assays are planned
According to the reviewers' suggestion, the paragraph on the primary outcome measures was revised. In the revised version of the abstract it now states, molecular signatures of all pregnant women with a preterm delivery will be included in the analysis and matched to controls with a term delivery. Secondary analysis will be dependent on numbers e.g. SGA rate is 20%; gestational diabetes 10%, malaria 3-5% and funding.
(see revised manuscript, line 624-629) p13 descriptive data: The first paragraph is rather unnecessary: You could just say appropriate descriptive statistics will be applied Response:
The paragraph that covered analysis plan of descriptive data was condensed to a minimum. (see revised manuscript, line 411) p13 descriptive data: The second paragraph is rather light and it is understandable if the data analysis plan is still to be developed, particularly considering the complexity of what is proposed.You may consider separating the laboratory/data pre-processing and statistical analysis sections (ie you mention mixed models on page 11 and they could be moved here). Line 37 needs to be expandeddo you mean the number of tests (and there for p value correction) may change if a more targeted research question is pursued? And/or you may consider only nominally significant associations? Do you have an idea of how you will address the high dimensionality of omic x omic x time? will you also apply multivariate or variable selection models? while your sample size analysis suggests a modular analysis will be feasible, different approaches will likely be required for genome-wide analyses.
Response: Indeed, in a clinical trial everything is and needs to adhere to a plan established in advance. But the type of study we are conducting is exploratory. Also, most of the value to be gained may be in the new approaches developed and lessons learned from solving unanticipated problems and addressing new challenges.
We are aiming to create an interactive dataset and believe others will have good ideas of how the data can be approached. The accessibility of the data set hopes to inspire questions and analytic plans that challenge researchers to make use of the clinical and 'omic' dimensions of this project.
However, as suggested, the methodology section was revised, and laboratory and data processing part were separated from the statistical aspect.
(see revised manuscript line 324, 409, 413-477)
We are glad that reviewer 1 addresses these concerns as this research is indeed conducted in a vulnerable population. Referring to the frequent blood sampling, we would like to emphasize that the fortnightly capillary blood sampling has been applied as a tool to screen for subclinical malaria infections in pregnant women in this study population for >30 years as the only control method (high levels of drug resistance malaria with no safe and effective prophylactic drugs available, bed nets did not prove effective in reducing malaria episodes in RCT in pregnant women). . This model describes that study participants are reimbursed for their expenses (e.g travel expenses) and for time away from work. The amount of money that will be reimbursed is adapted to the local situation (availability of taxi, or boats or other means of transport) and, according to the researcher experience, not enough to serve as an incentive to participate in the study. Moreover, the local community advisory board and the local ethical review board approved this research project with the given remittance for travel and compensation.
For the reviewer's information SMRU is one of the sites for the REACH project (see https://www.ethox.ox.ac.uk/Our-research/major-programmes/reach/ ) that is looking exactly at the points the reviewer has raised.
As perceived by the reviewer only a fraction of the pregnant women in this cohort are necessary to achieve the planned nested case-control aspect that tries to unravel preterm birth by analysing molecular signatures, data from a large number of study participants will not feed into this primary objective. However, since a wealth of data will be generated, the researchers will assess data derived from other phenotypes than preterm. As reviewer 1 pointed out, among other outcomes, birth weight (as birth weight for gestational age and sex defined using international standards) is one potential clinical phenotype that can be assessed, especially since small for gestational age affects more than 20% of newborns in this population. Other phenotypes commonly seen in this study population are maternal anaemia and/or helminth infestations. Depending on the sample size for other potential outcomes, the researchers will analyse quality of the captured data and determine whether results are valid. All valid results from any subgroup analysis will be made available for the scientific community and published in peer-reviewed journals.
Indeed, there are plans to follow the mother/infant pairs from this pregnancy cohort: an extension of the follow up period until 2 years post-partum has already been approved by the 2 independent ethical review boards and funding had been secured to realize this project. As stated in the main text, there is a plan to publish the study protocol that described procedures and outcomes for the postpartum period.
(see revised manuscript, line 624-629)
Reviewer: 2
Reviewer Name: Kenichi Sakurai, Chiba University, Japan
The authors would like to express their gratitude to Dr. Sakurai for the thorough review and his recommendations to improve this research protocol.
1. When will the authors start this cohort study? How long will they recruit their participants? Response:
In fact, recruitment of this study has already started on September 12 th , 2016. This is also indicated in the trial registration that is available at ClinicalTrials.gov under the identifier NCT02797327. Recruitment will continue until the sample size is reached and lost participants will be replaced. Overall the estimated recruitment period is about 18 months.
Response: The absence of prior high-resolution temporal profiling data in this setting precluded power calculations to be performed to determine sample size. We would be in a position to do so when the present work concludes, and indeed a potential next step could then be the design of an adequately powered multi-centre validation study.
In the absence of preliminary data, a pragmatic approach consists in recruiting a number of cases and controls from which a candidate biomarker signature with potential clinical relevance can reasonably be expected to be found. This number was in our case set to 30, which means that we consider it unlikely that a signature would be sufficiently robust to be of clinical relevance if it required a higher number of cases and controls to reach significance. This number is obviously selected empirically but our experience conducting blood transcriptomic studies across a wide range of study settings indicates that it would likely be sufficient to identify candidate signatures and assess phenotypic heterogeneity at the molecular level.
With a target number of cases being set (in our case to 30), the estimation of the cohort size is then simply based on documented PTB rates for the study population (in our case 400). The rate of PTB in this population is on the lower end of the spectrum and we also factored in the risk that as is the tradition some women deliver at home whereas the study needs to capture unit births. The explanation above has been added to the text. Please see line 225-247
3. The authors should describe the statistical methods to evaluate mRNA expression, microbiota composition and others. It will be helpful for the readers to understand the protocol (sample size setting etc.). Will the authors evaluate their data using adjustment for multiple testing, such as Bonferroni's method? Response: Multiple serial sampling profiles of participants will clearly require statistical methods that adjust for this. According to Reviewer #1 suggestion, the intended statistical analysis was expanded and separated from the data acquisition and the samples analysis part.
(Line 413-477 of the revised manuscript)
Manufacturers' names and links to the reagents that will be used in this research project are mentioned in the supplement material. Missing information concerning the protease and phosphatase inhibitor was added to Table S1 in the supplementary file. Platforms used to assess transcript abundance and microbial nucleic acid isolation and 16S rRNA gene sequencing are mentioned in the Methodology section 5. It seems to be difficult for me to understand figure 2. I would appreciate it if the authors can change it for easy understanding.
We appreciate this comment and revised figure 2, which describes the timeline of study
